Status: Recruiting
Efficacy of INM004 in Children With STEC-HUS
The objectives of this study are to evaluate the efficacy, safety, and pharmacokinetics of INM004 in pediatric patients with Hemolytic Uremic Syndrome associated to infection by Shiga toxin-producing Escherichia coli (STEC-HUS).
Participants needed: 220
Trial details
Phase: Phase 3Age: 9-17Biological sex: AllType: InterventionalSponsor: Inmunova S.A.Updated: Jan 15, 2026Locations: 52
Eligibility criteria
Age ≥ 9 months and < 18 years at the time of randomization. [+13]
Start of dialysis within 48 hours prior to admission to the participating instit... [+16]